Trial · NCT02525367
Online Cognitive Training in PD, MS and Depressed Patients Treated With Electroconvulsive Therapy
NCT02525367, Not applicable, Terminated, Amsterdam UMC, location VUmc
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Online Cognitive Training in PD, MS and Depressed Patients Treated With Electroconvulsive Therapy. Trials, record NCT02525367. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02525367
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Online Cognitive Training in PD, MS and Depressed Patients Treated With Electroconvulsive Therapy
- NCT number
- NCT02525367
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 28 participants, actual
- Lead sponsor
- Amsterdam UMC, location VUmc
- Conditions
- Idiopathic Parkinson's Disease, Multiple Sclerosis, Elderly Post Electric Convulsive Therapy
- Interventions
- Online cognitive training, Active control condition
- First posted
- 2015-08-17
- Last updated
- 2017-08-28
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Feasibility | 8 weeks | The feasibility of the intervention as reported by the patients on 4-point Likert scale items (T1) |
| Secondary | Trail Making Task | Baseline, 8 weeks and 12 weeks | Cognitive functioning as assessed by neuropsychological measures. These are measured by the interaction effect between time of measurement (T0 versus T1, or T0 versus T2) and condition (experimental versus active control). If possible, parallel tests will be used to correct for repeated neuropsychological testing. The objectively measured intervention effect will be assessed on the most affected cognitive domain, different per syndrome: \- PD and postECT: improvement in executive functions, measured by change in the Trail Making Task |
| Secondary | Cognitive functioning (subjectively measured) | Baseline, 8 weeks and 12 weeks | Change in subjective cognitive complaints as reported by the patient, measured by the Cognitive Failure Questionnaire (CFQ) |
| Secondary | Feasibility | Patients will be interviewed in a group session after study completion, an expected average of half a year | The feasibility of the intervention as reported by the patients in a group session lead by patients from the disease associations. |
| Secondary | Stroop Color Word Task | Baseline, 8 weeks and 12 weeks | Cognitive functioning as assessed by neuropsychological measures. These are measured by the interaction effect between time of measurement (T0 versus T1, or T0 versus T2) and condition (experimental versus active control). If possible, parallel tests will be used to correct for repeated neuropsychological testing. The objectively measured intervention effect will be assessed on the most affected cognitive domain, different per syndrome: \- PD and postECT: improvement in executive functions, measured by change in the Stroop Color Word Test. |
| Secondary | Letter Fluency | Baseline, 8 weeks and 12 weeks | Cognitive functioning as assessed by neuropsychological measures. These are measured by the interaction effect between time of measurement (T0 versus T1, or T0 versus T2) and condition (experimental versus active control). If possible, parallel tests will be used to correct for repeated neuropsychological testing. The objectively measured intervention effect will be assessed on the most affected cognitive domain, different per syndrome: \- PD and postECT: improvement in executive functions, measured by change in the Letter Fluency. |
| Secondary | Rey Auditory Verbal Learning Test | Baseline, 8 weeks and 12 weeks | Cognitive functioning as assessed by neuropsychological measures. These are measured by the interaction effect between time of measurement (T0 versus T1, or T0 versus T2) and condition (experimental versus active control). If possible, parallel tests will be used to correct for repeated neuropsychological testing. The objectively measured intervention effect will be assessed on the most affected cognitive domain, different per syndrome: \- MS: improvement in episodic memory, measured by change in the Rey Auditory Verbal Learning Test. |
| Secondary | Location Learning Test | Baseline, 8 weeks and 12 weeks | Cognitive functioning as assessed by neuropsychological measures. These are measured by the interaction effect between time of measurement (T0 versus T1, or T0 versus T2) and condition (experimental versus active control). If possible, parallel tests will be used to correct for repeated neuropsychological testing. The objectively measured intervention effect will be assessed on the most affected cognitive domain, different per syndrome: \- MS: improvement in episodic memory, measured by change in the Location Learning Test. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers17
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02525367
GET https://conductscience.org/api/trials/v1/NCT02525367/registered